HepPar-1 - Revision history

Michael at 16:22, 22 November 2019

2019-11-22T16:22:22Z

← Older revision		Revision as of 16:22, 22 November 2019
Line 7:		Line 7:
	*[[Gastric adenocarcinoma]].		*[[Gastric adenocarcinoma]].
	*[[Lung adenocarcinoma]] - especially [[SMARCA4-deficient non-small cell carcinoma of the lung]].<ref name=pmid28555282>{{Cite journal \| last1 = Agaimy \| first1 = A. \| last2 = Fuchs \| first2 = F. \| last3 = Moskalev \| first3 = EA. \| last4 = Sirbu \| first4 = H. \| last5 = Hartmann \| first5 = A. \| last6 = Haller \| first6 = F. \| title = SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 \| journal = Virchows Arch \| volume = 471 \| issue = 5 \| pages = 599-609 \| month = Nov \| year = 2017 \| doi = 10.1007/s00428-017-2148-5 \| PMID = 28555282 }}</ref>		*[[Lung adenocarcinoma]] - especially [[SMARCA4-deficient non-small cell carcinoma of the lung]].<ref name=pmid28555282>{{Cite journal \| last1 = Agaimy \| first1 = A. \| last2 = Fuchs \| first2 = F. \| last3 = Moskalev \| first3 = EA. \| last4 = Sirbu \| first4 = H. \| last5 = Hartmann \| first5 = A. \| last6 = Haller \| first6 = F. \| title = SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 \| journal = Virchows Arch \| volume = 471 \| issue = 5 \| pages = 599-609 \| month = Nov \| year = 2017 \| doi = 10.1007/s00428-017-2148-5 \| PMID = 28555282 }}</ref>

			==See also==
			*[[Hepatocellular carcinoma]].
			*[[Liver metastasis]].
			*[[Immunohistochemistry]].

	==References==		==References==

Michael at 16:20, 22 November 2019

2019-11-22T16:20:57Z

← Older revision		Revision as of 16:20, 22 November 2019
Line 3:		Line 3:
	==Positive==		==Positive==
	*[[Hepatocellular carcinoma]] - 18/19 cases.<ref>{{Cite journal \| last1 = Fan \| first1 = Z. \| last2 = van de Rijn \| first2 = M. \| last3 = Montgomery \| first3 = K. \| last4 = Rouse \| first4 = RV. \| title = Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. \| journal = Mod Pathol \| volume = 16 \| issue = 2 \| pages = 137-44 \| month = Feb \| year = 2003 \| doi = 10.1097/01.MP.0000052103.13730.20 \| PMID = 12591966 }}</ref>		*[[Hepatocellular carcinoma]] - 18/19 cases.<ref>{{Cite journal \| last1 = Fan \| first1 = Z. \| last2 = van de Rijn \| first2 = M. \| last3 = Montgomery \| first3 = K. \| last4 = Rouse \| first4 = RV. \| title = Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. \| journal = Mod Pathol \| volume = 16 \| issue = 2 \| pages = 137-44 \| month = Feb \| year = 2003 \| doi = 10.1097/01.MP.0000052103.13730.20 \| PMID = 12591966 }}</ref>

			===Occasionally positive===
			*[[Gastric adenocarcinoma]].
			*[[Lung adenocarcinoma]] - especially [[SMARCA4-deficient non-small cell carcinoma of the lung]].<ref name=pmid28555282>{{Cite journal \| last1 = Agaimy \| first1 = A. \| last2 = Fuchs \| first2 = F. \| last3 = Moskalev \| first3 = EA. \| last4 = Sirbu \| first4 = H. \| last5 = Hartmann \| first5 = A. \| last6 = Haller \| first6 = F. \| title = SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 \| journal = Virchows Arch \| volume = 471 \| issue = 5 \| pages = 599-609 \| month = Nov \| year = 2017 \| doi = 10.1007/s00428-017-2148-5 \| PMID = 28555282 }}</ref>

	==References==		==References==

Michael at 16:18, 22 November 2019

2019-11-22T16:18:32Z

← Older revision		Revision as of 16:18, 22 November 2019
Line 5:		Line 5:

	==References==		==References==
	{{~~Relist~~\|1}}		{{Reflist\|1}}

	[[Category:Immunohistochemistry]]		[[Category:Immunohistochemistry]]

Michael: Created page with "'''HepPar-1''' is an commonly used immunostain. ==Positive== *Hepatocellular carcinoma - 18/19 cases.{{Cite journal | last1 = Fan | first1 = Z. | last2 = van de..."

2019-11-22T16:18:22Z

Created page with "'''HepPar-1''' is an commonly used immunostain. ==Positive== *Hepatocellular carcinoma - 18/19 cases.<ref>{{Cite journal | last1 = Fan | first1 = Z. | last2 = van de..."

New page

'''HepPar-1''' is an commonly used [[immunostain]].

==Positive==
*[[Hepatocellular carcinoma]] - 18/19 cases.<ref>{{Cite journal | last1 = Fan | first1 = Z. | last2 = van de Rijn | first2 = M. | last3 = Montgomery | first3 = K. | last4 = Rouse | first4 = RV. | title = Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. | journal = Mod Pathol | volume = 16 | issue = 2 | pages = 137-44 | month = Feb | year = 2003 | doi = 10.1097/01.MP.0000052103.13730.20 | PMID = 12591966 }}</ref>

==References==
{{Relist|1}}

[[Category:Immunohistochemistry]]